Contact
searchSearch
HMP Global
Video AMP 2023

CLI in the Setting of Mixed Arterial and Venous Disease

Fadi A. Saab, MD, FASE, FACC, FSCAI

Advanced Cardiac and Vascular Centers, Grand Rapids, Michigan

06/28/2023

In this CLI case, a patient presents with mixed arterial and venous disease with leg discomfort at rest and with activity with noncompressible ABIs suggesting tibial artery disease. This case demonstrates the use of IVUS to detect discreet lesions that often go undetected with the use of angiogram imaging alone.

Join us at the 2023 Amputation Prevention Symposium (AMP), taking place August 16-19 in Chicago, to see similar complex cases performed live by expert operators.

About Us

Vascular Disease Management™ (VDM), the official media partner of the International Symposium on Endovascular Therapy (ISET) and the Amputation Prevention Symposium (AMP), is a peer-reviewed journal that educates readers on the latest advancements in endovascular treatment strategies. 

Learn more about ISET and AMP and register for the events here:

ISET logo

AMP logo

Subscribe Now!

Vascular Disease Management Newsletter

News

Carotid REvascularization
Contego Medical Receives FDA Approval for Neuroguard IEP Direct System for Transcarotid Artery Revascularization with Integrated Embolic Protection (TCAR-IEP)
11/11/2026
The Neuroguard IEP 3-in-1 system was previously studied for transfemoral and transradial carotid stenting in the PERFORMANCE I and PERFORMANCE II studies. It received FDA PMA approval in October 2024 and is commercially distributed by...
The Neuroguard IEP 3-in-1 system was previously studied for transfemoral and transradial carotid stenting in the PERFORMANCE I and PERFORMANCE II studies. It received FDA PMA approval in October 2024 and is commercially distributed by...
The Neuroguard IEP 3-in-1 system...
11/11/2026
Cath Lab Digest
Stroke Prevention
FDA Approval of Asundexian Provides a New Approach to Secondary Stroke Prevention
11/10/2026
Asundexian (Sunharbo; Bayer) gives clinicians a new option: a once-daily oral Factor XIa inhibitor added to antiplatelet therapy to reduce the risk of stroke in adults with recent noncardioembolic ischemic stroke or high-risk TIA.
Asundexian (Sunharbo; Bayer) gives clinicians a new option: a once-daily oral Factor XIa inhibitor added to antiplatelet therapy to reduce the risk of stroke in adults with recent noncardioembolic ischemic stroke or high-risk TIA.
Asundexian (Sunharbo; Bayer)...
11/10/2026
Vascular Disease Management
LAA Occluders
Late-Breaking One-Year Data Show Abbott's Next-Generation Amulet 360™ Device Continues to Demonstrate High Rates of Left Atrial Appendage Closure and Low Incidence of Stroke
11/03/2026
Late-breaking one-year VERITAS study results were presented at the Transcatheter Cardiovascular Therapeutics conference and simultaneously published in JACC: Cardiovascular Interventions;data show the device achieved high closure rates of...
Late-breaking one-year VERITAS study results were presented at the Transcatheter Cardiovascular Therapeutics conference and simultaneously published in JACC: Cardiovascular Interventions;data show the device achieved high closure rates of...
Late-breaking one-year...
11/03/2026
Vascular Disease Management
Intravascular Lithotripsy
Abbott's TECTONIC Clinical Trial Demonstrates Strong 30-day Outcomes and High Procedural Success for Its Investigational SonicForce™ Coronary Intravascular Lithotripsy System
11/03/2026
11/03/2026
Vascular Disease Management
Stroke Clinical Trials
Could A Drug for Leg Cramps Prevent a Second, Deadlier Stroke? 
10/30/2026
The trial is funded by the National Institute of Neurological Disorders and Stroke (NINDS) and is open to patients diagnosed within the last six months with an ischemic stroke or high-risk transient ischemic attack (TIA).
The trial is funded by the National Institute of Neurological Disorders and Stroke (NINDS) and is open to patients diagnosed within the last six months with an ischemic stroke or high-risk transient ischemic attack (TIA).
The trial is funded by the...
10/30/2026
Cath Lab Digest
Radiation Safety
Rampart Launches Vanguard™ at TCT 2026, Extending Total-Body Radiation Protection to Interventional Imagers
10/29/2026
Purpose-built head-of-table solution advances the Shed the Lead® movement as new multisociety guidance calls for enhanced radiation protection.
Purpose-built head-of-table solution advances the Shed the Lead® movement as new multisociety guidance calls for enhanced radiation protection.
Purpose-built head-of-table...
10/29/2026
Vascular Disease Management
Peripheral Arterial Bleeds
Instylla's Embrace® Hydrogel Embolic System Receives FDA Approval for Peripheral Arterial Bleeds
10/29/2026
10/29/2026
Vascular Disease Management
Large-Bore Closure
Haemonetics Announces FDA Approval of PerQseal Elite Vascular Closure System
10/27/2026
The PerQseal Elite system provides sutureless, large-bore vascular closure following structural heart and endovascular procedures performed with 14 – 22F sheaths. Its fully bioabsorbable patch seals arteriotomies up to 26F from within the...
The PerQseal Elite system provides sutureless, large-bore vascular closure following structural heart and endovascular procedures performed with 14 – 22F sheaths. Its fully bioabsorbable patch seals arteriotomies up to 26F from within the...
The PerQseal Elite system...
10/27/2026
Cath Lab Digest
FDA Approvals
Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT)
10/20/2026
ALAMEDA, Calif. -- Penumbra, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted clearance for the treatment of deep vein thrombosis (DVT) to the company's Lightning™ computer assisted vacuum thrombectomy (CAVT™)...
ALAMEDA, Calif. -- Penumbra, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted clearance for the treatment of deep vein thrombosis (DVT) to the company's Lightning™ computer assisted vacuum thrombectomy (CAVT™)...
ALAMEDA, Calif. -- Penumbra,...
10/20/2026
Cath Lab Digest
Vertex PE System (Jupiter Endovascular)
Pulmonary Embolism
Jupiter Endovascular Announces Publication of SPIRARE II Pivotal Trial Results Showing Vertex Thrombectomy System Normalized Hemodynamics in 50% of Pulmonary Embolism Patients
10/19/2026
The Vertex system leverages the company’s proprietary Transforming Fixation (TFX) platform technology, a single catheter designed to navigate flexibly through the right heart and stabilize on-demand in the pulmonary arteries for precise,...
The Vertex system leverages the company’s proprietary Transforming Fixation (TFX) platform technology, a single catheter designed to navigate flexibly through the right heart and stabilize on-demand in the pulmonary arteries for precise,...
The Vertex system leverages the...
10/19/2026
Cath Lab Digest

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use